BioCentury
ARTICLE | Finance

Regulatory milestones

Highlights of weekly biotech stock moves

May 31, 2010 7:00 AM UTC

Regulatory milestones

Alkermes Inc. (NASDAQ:ALKS) was up $0.56 to $11.35 last week after FDA accepted for filing and granted Priority Review to an sNDA for Vivitrol naltrexone to treat opioid dependence. The injectable sustained-release formulation of naltrexone has an Oct. 12 PDUFA date...